ArticleOphthalmology science2023

Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials.

Rose Edmonds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.